Developer docs
API playgroundTry for free, no card

Search company profiles

Glamorous AI

Full company profile

uuid0003iys

Namestring
Glamorous AI
Websiteurl
glamorous.ai
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Glamorous AI is a privately held, London-based company developing an artificial intelligence-based drug discovery platform. Founded in 2020, the company operates with a small team of 1–10 employees and positions itself within the AI-driven pharmaceutical R&D segment, applying machine learning techniques to the early-stage drug discovery workflow. The firm's product surface, technical architecture, and customer-facing offerings are not publicly disclosed; the company's website displays a verification/loading page, and there is no documented product, pricing, or integration footprint in the available data.

The company has been funded primarily through non-dilutive and accelerator-style capital rather than large venture rounds. Its known funding events include a £440,000 grant from Innovate UK in April 2021, participation in the MassChallenge accelerator in June 2021, and an unstated-amount round involving Cur8 Capital dated January 2023. No follow-on venture funding of meaningful scale has been disclosed in the data set. There is no information on revenue model, pricing, customer segments, or partnerships in the available source material.

Operationally, the company appears to be in an early validation phase. Leadership is anchored by co-founder Mohamed AbouZleikha, who serves as Vice President and Head of AI Product Development, suggesting AI/ML capability is core to the value proposition rather than a peripheral feature. However, with no disclosed product releases, customer logos, headcount growth, or geographic footprint beyond its London base, observable commercial traction is minimal and the company remains in pre-commercial or very early-commercial stages.

Short descriptiontext

Glamorous AI is a London-based, privately held startup founded in 2020 that develops an artificial intelligence-based drug discovery platform. The company operates with a small team (1–10 employees) and has been funded primarily through Innovate UK grants and accelerator participation.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
AI drug discovery, computational biology, generative chemistry, pharmaceutical AI, molecular design
Industry1 code
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
AI Drug Discovery Platform
Social media profiles2 records
Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Glamorous AI develops an artificial intelligence-based drug discovery platform intended to support computational drug discovery and molecular design. The company provides AI-driven tooling aimed at pharmaceutical and biotechnology researchers seeking to accelerate early-stage drug development.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1AI Drug Discovery Platform
CategoryAI Drug Discovery Software
Description

Artificial intelligence-based drug discovery platform that applies AI/ML to molecular design and early-stage pharmaceutical research, intended for pharmaceutical and biotechnology research teams.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Glamorous AI

AI Drug Discovery Platformglamorous.ai

Glamorous AI is a London-based, privately held startup founded in 2020 that develops an artificial intelligence-based drug discovery platform. The company operates with a small team (1–10 employees) and has been funded primarily through Innovate UK grants and accelerator participation.

What Glamorous AI does

Glamorous AI is a privately held, London-based company developing an artificial intelligence-based drug discovery platform. Founded in 2020, the company operates with a small team of 1–10 employees and positions itself within the AI-driven pharmaceutical R&D segment, applying machine learning techniques to the early-stage drug discovery workflow. The firm's product surface, technical architecture, and customer-facing offerings are not publicly disclosed; the company's website displays a verification/loading page, and there is no documented product, pricing, or integration footprint in the available data.

The company has been funded primarily through non-dilutive and accelerator-style capital rather than large venture rounds. Its known funding events include a £440,000 grant from Innovate UK in April 2021, participation in the MassChallenge accelerator in June 2021, and an unstated-amount round involving Cur8 Capital dated January 2023. No follow-on venture funding of meaningful scale has been disclosed in the data set. There is no information on revenue model, pricing, customer segments, or partnerships in the available source material.

Operationally, the company appears to be in an early validation phase. Leadership is anchored by co-founder Mohamed AbouZleikha, who serves as Vice President and Head of AI Product Development, suggesting AI/ML capability is core to the value proposition rather than a peripheral feature. However, with no disclosed product releases, customer logos, headcount growth, or geographic footprint beyond its London base, observable commercial traction is minimal and the company remains in pre-commercial or very early-commercial stages.

Glamorous AI firmographics

Firmographics
Name
Glamorous AI
Website
https://glamorous.ai
Company type
Private
Founded year
2020
Headcount range
1–10 employees
Short description
Glamorous AI is a London-based, privately held startup founded in 2020 that develops an artificial intelligence-based drug discovery platform. The company operates with a small team (1–10 employees) and has been funded primarily through Innovate UK grants and accelerator participation.
Ownership category
akta.pro rank

Glamorous AI industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Computational biology
  • Generative chemistry
  • Pharmaceutical AI
  • Molecular design

Where Glamorous AI is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Glamorous AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel

Glamorous AI product offering

Product offering

Core offering

Glamorous AI develops an artificial intelligence-based drug discovery platform intended to support computational drug discovery and molecular design. The company provides AI-driven tooling aimed at pharmaceutical and biotechnology researchers seeking to accelerate early-stage drug development.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI Drug Discovery Platform Artificial intelligence-based drug discovery platform that applies AI/ML to molecular design and early-stage pharmaceutical research, intended for pharmaceutical and biotechnology research teams.

Companies that use Glamorous AI

Customer profile

Ideal customer profiles1 record

Glamorous AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Glamorous AI partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

Glamorous AI competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Glamorous AI social profiles

Digital presence

Glamorous AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Glamorous AI leadership team

Management profile

Number of profiles

Profiles1 record

Glamorous AI funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Glamorous AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glamorous AI

What does Glamorous AI do?

Glamorous AI develops an artificial intelligence-based drug discovery platform intended to support computational drug discovery and molecular design. The company provides AI-driven tooling aimed at pharmaceutical and biotechnology researchers seeking to accelerate early-stage drug development.

When was Glamorous AI founded?

Glamorous AI was founded in 2020. It employs 1 to 10 people.

Where is Glamorous AI based?

Glamorous AI is headquartered in London, United Kingdom, in the Europe region.

Does Glamorous AI have an API?

No public API is recorded for Glamorous AI.

What industry is Glamorous AI in?

Glamorous AI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals